Restless Legs Syndrome (RLS) and Iron

Deep Dive

From a Western medicine perspective, the iron–RLS connection is one of the clearest biologic and therapeutic links in sleep neurology. Iron is i... From a Western medicine perspective, the iron–RLS connection is one of the clearest biologic and therapeutic links in sleep neurology. Iron is integral to the dopaminergic system because it is a required cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Imaging and biochemical studies consistently show reduced brain iron in RLS, particularly in the substantia nigra and related basal ganglia structures that modulate sensorimotor function. These abnormalities can exist even when circulating iron indices are within reference ranges, implicating altered transport across the blood–brain barrier, upregulated hepcidin from inflammation, and genetic variants such as MEIS1 and BTBD9 that influence iron handling and neuronal development. Clinically, RLS is more common among individuals with systemic iron deficiency, in pregnancy, and in chronic kidney disease—contexts in which iron availability is compromised. Laboratory evaluation typically includes ferritin, transferrin saturation, serum iron, total iron-binding capacity, a complete blood count to assess anemia, and C-reactive protein to interpret ferritin in the setting of inflammation. Many guidelines consider lower ferritin and low transferrin saturation as thresholds that prompt iron repletion, with the understanding that ferritin is an acute-phase reactant and may be misleadingly normal during inflammation. Treatment strategies prioritize restoring iron availability. Oral iron is a reasonable first step for those with documented low or borderline stores, though gastrointestinal intolerance and reduced absorption—especially with acid-suppressing medications—can limit efficacy. Randomized trials and a Cochrane meta-analysis indicate that intravenous iron provides more rapid and consistent symptom relief, particularly in individuals with low ferritin or low transferrin saturation or those who fail oral therapy. Benefits often emerge within weeks for IV iron and may take longer with oral regimens. Safety considerations include monitoring for iron overload, rare hypersensitivity reactions with IV formulations, and hypophosphatemia associated with some products. Because iron can reduce absorption of other medications (e.g., levodopa, certain antibiotics, and thyroid hormone), timing and co-administration need attention. Pharmacologic therapies such as alpha-2-delta ligands or dopamine agonists remain options when iron repletion is insufficient, with careful monitoring for augmentation and adverse effects. Persistent or complex cases—for example, in pregnancy or CKD—warrant specialist involvement to individualize care and monitoring.